Drugs / LY2979165
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07492771 | Jun → Dec 2026 expected | pneumonia caused by pseudomonas aeruginosa infection | Microbiotix, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01524237 | Apr 2012 → Jul 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01383967 | Jul 2011 → Jun 2012 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01248052 | Nov 2010 → May 2011 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03044249 | May 2017 → Jan 2020 | Alzheimer disease, psychotic disorder | Mediti Pharma Inc. | Terminated | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT02246816 | Feb 2015 → Feb 2018 | short bowel syndrome | Marathon Pharmaceuticals, LLC | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2979165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01524237 ↗ |
| Known as | MP-101 | “The investigational product, MP101, is a cocktail formulation comprising two bacteriophages.” NCT07492771 ↗ |
| Known as | Opium Tincture (OT) | “0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)” NCT02246816 ↗ |
| Modality | Other / unclassified | “The investigational product, MP101, is a cocktail formulation comprising two bacteriophages.” NCT07492771 ↗ |
| Route | Oral | “administered orally” NCT01248052 ↗ |